Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapies for cancer and chronic degenerative diseases. Its primary platforms focus on telomerase inhibitors (imetelstat), telomerase cancer vaccines (GRNVAC1), and human embryonic stem cell (hESC) therapies (e.g., GRNOPC1 for spinal cord injury). The company has no approved products and relies on collaboration agreements and licensing for revenue.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2009 |
|---|---|---|---|
| Total Revenues | $546 | $2,465 | $1,121 |
| Net Loss | $(18,344) | $(52,015) | $(51,793) |
| Net Loss Per Share (Basic/Diluted) | $(0.19) | $(0.54) | $(0.59) |
| Research & Development Expenses | $13,728 | $40,662 | $42,278 |
| General & Administrative Expenses | $5,021 | $13,359 | $10,705 |
| Cash and Cash Equivalents | $34,490 | $34,490 | $97,869 (End of Period 2009) |
| Total Marketable Securities | $110,913 | $110,913 | $131,678 (End of Period 2009) |
| Accumulated Deficit | $(629,282) | $(629,282) | $(577,267) |
Liquidity: As of September 30, 2010, total cash, restricted cash, and marketable securities totaled approximately $146.2 million. Management estimates these resources are sufficient to fund operations through at least December 2011.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues for the nine months ended September 30, 2010, increased to $2.5 million from $1.1 million in the prior year period. This was driven primarily by license fee revenues from the GE Healthcare UK Limited (GEHC) collaboration and increased royalties.
- Operating Expenses: Research and development (R&D) expenses decreased slightly for the nine-month period ($40.7M vs. $42.3M) due to reduced manufacturing costs for the GRNVAC1 vaccine following patient enrollment completion. However, R&D expenses for the three-month period increased ($13.7M vs. $13.4M) due to the startup of Phase II imetelstat trials and Phase I GRNOPC1 trials.
- General & Administrative (G&A): G&A expenses increased significantly for the nine-month period ($13.4M vs. $10.7M), primarily due to higher stock-based compensation ($1.6M increase) and legal costs related to intellectual property.
- Derivative Valuation: The company recorded an unrealized loss of $97,000 on derivatives for the quarter, compared to a gain of $966,000 in the prior year quarter, reflecting fluctuations in the fair value of warrant liabilities.
Outlook, Risks, and Unusual Items
- Clinical Progress:
- Imetelstat: Phase II trials for non-small cell lung cancer and multiple myeloma are ongoing. Phase I trials in other malignancies are complete.
- GRNOPC1: The FDA lifted a clinical hold in July 2010. The first patient was enrolled in the Phase I trial for acute spinal cord injury in October 2010.
- GRNVAC1: Patient enrollment for the Phase II trial in acute myelogenous leukemia is complete; results are pending.
- Subsequent Event: In October 2010, GEHC launched the first human cellular assay product, triggering a milestone payment to Geron.
- Capital Needs: The company anticipates needing substantial additional capital to continue clinical development. Future funding may be sought through strategic collaborations, equity financings, or debt, which could result in dilution.
- Risks:
- Regulatory: Uncertainty regarding FDA approvals and potential restrictions on hESC research funding.
- Intellectual Property: Ongoing patent interferences and oppositions (e.g., with ViaCyte and KAEL-GemVax) regarding hESC and telomerase technologies.
- Financial: History of losses with an accumulated deficit of $629.3 million; no expectation of profitability in the near term.
Investor Verification Checklist
- Cash Runway: Verify if the $146.2 million in liquid assets is sufficient to fund the planned Phase II trials for imetelstat and GRNOPC1 through the end of 2011 without additional financing.
- Revenue Sustainability: Assess the reliance on the GEHC collaboration for revenue, noting that current revenues may not be predictive of future therapeutic product sales.
- Patent Status: Monitor the outcomes of the patent interference with ViaCyte and the opposition proceedings in Europe regarding hESC patents, as these are critical to the company's proprietary position.
- Clinical Milestones: Track the safety and efficacy data from the ongoing Phase II imetelstat trials and the Phase I GRNOPC1 trial, as these are the primary value drivers.
- Stock-Based Compensation: Review the impact of non-cash stock-based compensation ($10.4M for the nine months) on operating expenses and potential future dilution.